XOMA Stock Overview
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$20.84|
|52 Week High||US$37.50|
|52 Week Low||US$16.96|
|1 Month Change||22.16%|
|3 Month Change||-25.86%|
|1 Year Change||-37.42%|
|3 Year Change||37.83%|
|5 Year Change||199.00%|
|Change since IPO||-99.71%|
Recent News & Updates
|XOMA||US Biotechs||US Market|
Return vs Industry: XOMA underperformed the US Biotechs industry which returned -27% over the past year.
Return vs Market: XOMA underperformed the US Market which returned -21.7% over the past year.
|XOMA Average Weekly Movement||11.7%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: XOMA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: XOMA's weekly volatility (12%) has been stable over the past year.
About the Company
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.
XOMA Fundamentals Summary
|XOMA fundamental statistics|
Is XOMA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|XOMA income statement (TTM)|
|Cost of Revenue||US$166.00k|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||1.05|
|Net Profit Margin||29.45%|
How did XOMA perform over the long term?See historical performance and comparison
Is XOMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for XOMA?
Other financial metrics that can be useful for relative valuation.
|What is XOMA's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does XOMA's PE Ratio compare to its peers?
|XOMA PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
LJPC La Jolla Pharmaceutical
CPRX Catalyst Pharmaceuticals
ORGO Organogenesis Holdings
Price-To-Earnings vs Peers: XOMA is expensive based on its Price-To-Earnings Ratio (19.8x) compared to the peer average (12.1x).
Price to Earnings Ratio vs Industry
How does XOMA's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Earnings vs Industry: XOMA is expensive based on its Price-To-Earnings Ratio (19.8x) compared to the US Biotechs industry average (15.4x)
Price to Earnings Ratio vs Fair Ratio
What is XOMA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||19.8x|
|Fair PE Ratio||36.6x|
Price-To-Earnings vs Fair Ratio: XOMA is good value based on its Price-To-Earnings Ratio (19.8x) compared to the estimated Fair Price-To-Earnings Ratio (36.6x).
Share Price vs Fair Value
What is the Fair Price of XOMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate XOMA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate XOMA's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: XOMA is good value based on its PEG Ratio (0.3x)
Discover undervalued companies
How is XOMA forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XOMA's forecast earnings growth (58.1% per year) is above the savings rate (1.9%).
Earnings vs Market: XOMA's earnings (58.1% per year) are forecast to grow faster than the US market (13.6% per year).
High Growth Earnings: XOMA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: XOMA's revenue (21.4% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: XOMA's revenue (21.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XOMA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has XOMA performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XOMA has high quality earnings.
Growing Profit Margin: XOMA's current net profit margins (29.4%) are higher than last year (19.5%).
Past Earnings Growth Analysis
Earnings Trend: XOMA has become profitable over the past 5 years, growing earnings by 49.3% per year.
Accelerating Growth: XOMA's earnings growth over the past year (113.2%) exceeds its 5-year average (49.3% per year).
Earnings vs Industry: XOMA earnings growth over the past year (113.2%) exceeded the Biotechs industry 98.2%.
Return on Equity
High ROE: XOMA's Return on Equity (14.9%) is considered low.
Discover strong past performing companies
How is XOMA's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: XOMA's short term assets ($89.6M) exceed its short term liabilities ($7.9M).
Long Term Liabilities: XOMA's short term assets ($89.6M) exceed its long term liabilities ($11.3M).
Debt to Equity History and Analysis
Debt Level: XOMA is debt free.
Reducing Debt: XOMA currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Debt Coverage: XOMA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: XOMA has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is XOMA current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XOMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate XOMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XOMA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XOMA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as XOMA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jim Neal (66 yo)
Mr. James R. Neal, also known as Jim, serves as Director at Palisade Bio, Inc. (Alternate name: Leading BioSciences Inc) since October 30, 2018 and serves as its Chairman of the Board since April 27, 2021...
CEO Compensation Analysis
Compensation vs Market: Jim's total compensation ($USD3.51M) is above average for companies of similar size in the US market ($USD1.79M).
Compensation vs Earnings: Jim's compensation has increased by more than 20% in the past year.
Experienced Board: XOMA's board of directors are considered experienced (5.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
XOMA Corporation's employee growth, exchange listings and data sources
- Name: XOMA Corporation
- Ticker: XOMA
- Exchange: NasdaqGM
- Founded: 1981
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$238.012m
- Shares outstanding: 11.42m
- Website: https://www.xoma.com
Number of Employees
- XOMA Corporation
- 2200 Powell Street
- Suite 310
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/01 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.